Project factsheets

Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).

IHI/IMI2/IMI1

Status

Call

Programmes

Disease areas

Products

Tools and resources to improve drug development

ALL # A B C D E F G H I K L M N O P Q R S T U V W Z

Clear all filters

Displaying 21 projects and 1 programmes

ADAPTED

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

CARE

Corona accelerated R&D in Europe

Ongoing IMI2 Respiratory diseases Infectious diseases Coronaviruses Conducting clinical trials Target identification Drug discovery

ESCulab

European screening centre; unique library for attractive biology

Closed IMI2 Target identification Drug discovery

EUbOPEN

EUbOPEN: Enabling and unlocking biology in the OPEN

Ongoing IMI2 Target identification Drug discovery

IMPRiND

Inhibiting misfolded protein propagation in neurodegenerative diseases

Closed IMI2 Neurodegenerative diseases Alzheimer's disease Stem cells Target identification Drug discovery

MELLODDY

Machine learning ledger orchestration for drug discovery

Closed IMI2 Tools for predicting/monitoring efficacy Tools for predicting/monitoring safety Big data and knowledge management Drug discovery Artificial intelligence

NGN-PET

Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments

Closed IMI2 Pain Real-world data, evidence Drug discovery

PD-MitoQUANT

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

Closed IMI2 Neurodegenerative diseases Tools for predicting/monitoring efficacy Disease taxonomy Target identification Drug discovery

PHAGO

Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33

Closed IMI2 Neurodegenerative diseases Alzheimer's disease Stem cells Target identification Drug discovery

PRISM

Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Closed IMI2 Neurodegenerative diseases Psychiatric diseases Alzheimer's disease Clinical trial design Disease taxonomy Target identification Drug discovery

ELF

European Lead Factory

Closed IMI1 Drug discovery

ENABLE

European Gram-negative Antibacterial Engine

Closed IMI1 Antimicrobial resistance Infectious diseases ND4BB Drug discovery

EU-AIMS

European Autism Interventions - a Multicentre Study for Developing New Medications

Closed IMI1 Psychiatric diseases Autism Tools for predicting/monitoring safety Clinical trial design Stem cells Drug discovery

EUROPAIN

Understanding chronic pain and improving its treatment

Closed IMI1 Pain Tools for predicting/monitoring safety Clinical trial design Drug discovery

K4DD

Kinetics for Drug Discovery

Closed IMI1 Tools for predicting/monitoring efficacy Tools for predicting/monitoring safety Drug discovery

ND4BB

New Drugs for Bad Bugs

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model

NEWMEDS

Novel methods leading to new medications in depression and schizophrenia

Closed IMI1 Psychiatric diseases Tools for predicting/monitoring safety Clinical trial design Drug discovery

Open PHACTS

The Open Pharmacological Concepts Triple Store

Closed IMI1 Big data and knowledge management Drug discovery

Pharma-Cog

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development

Closed IMI1 Neurodegenerative diseases Alzheimer's disease Tools for predicting/monitoring safety Clinical trial design Drug discovery

SUMMIT

Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools

Closed IMI1 Diabetes & metabolic disorders Tools for predicting/monitoring safety Clinical trial design Drug discovery

TRANSLOCATION

Molecular basis of the bacterial cell wall permeability

Closed IMI1 Antimicrobial resistance Infectious diseases ND4BB Drug discovery

ULTRA-DD

Unrestricted leveraging of targets for research advancement and drug discovery

Closed IMI1 Autoimmune diseases Drug discovery